Canada Markets close in 2 hrs 5 mins

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3380-0.0020 (-0.59%)
As of 01:26PM EDT. Market open.
Sign in to post a message.
  • M
    M - good M
    I feel so bad for those who are selling now...
  • M
    Mark
    nice jump this morning on the Canadian side...the equivalent to $.38 US...hopefully we open tomorrow in the states and hit $.40
  • T
    T-BAGS
    Let's get it
  • C
    Cor
    Within now and a few weeks everyone in the world will be becoming familiair which and what Bucillamine means. It will turn out to be a very good working medicine to fight Covid-19.
  • l
    luca
    This feels like an eternity
  • J
    Joejoe
    who agrees 1 dollar by next week after news starts coming out
  • C
    Cor
    Our waiting in patience holders, will be rewarded, I am sure. This stockprices in this range; we will see them never again. GLTA, believers in Revive.
  • M
    Mike
    Thinking buyout by the end of August. I believe it's already been discussed, just have to get through the process.
  • J
    Joejoe
    get in while its at this price discounted wow
  • B
    BadM
    Might be a good idea to load up in Canada tomorrow July 4 before this reeeely takes off
  • B
    Benjamin
    Wow... Paxlovid failed NIAID Director, Anthony Fauci, according to this Bloomberg health reporter tweet. Failure doesn't get more high-profile than this... We need other oral therapeutic solutions ASAP. Whatever happens from here, Bucy has a next-in-line opportunity to break through.

    https://twitter.com/rileyraygriffin/status/1541902615101018114

    Paxlovid efficacy rate cut in half: https://thedalesreport.com/trends/efficacy-of-pfizers-paxlovid-covid-drug-crashes-according-to-nih-funded-study/
    A new National Institutes of Health funded study shows waning effectiveness of Pfizer's Paxlovid for patient hospitalizations due to COVID
    A new National Institutes of Health funded study shows waning effectiveness of Pfizer's Paxlovid for patient hospitalizations due to COVID
    thedalesreport.com
  • B
    Benjamin
    This is a story I feel is important and why I am bullish on the prospects here. No, Bucillamine isn't being tested for "long COVID" endpoints in the current trial. However, this drug fits the profile as an ideal option for long COVID sufferers with anti-inflam/anti-ox/anti-spike protein binding ability. If it gets approved for current endpoints, you can be sure this will be used off-label and tested in a separate Ph3 trial for 'long COVID' symptoms by whichever Tier-1 Pharma company that acquires the asset. JMHO.

    Opening paragraph; "A majority of people with Long Covid who are registered with state benefits agency UWV have been so disabled by the virus they are no longer fit for work."

    https://www.dutchnews.nl/news/2022/06/over-half-of-people-with-long-covid-for-two-years-are-declared-unfit-to-work/
    A majority of people with Long Covid who are registered with state benefits agency UWV have been so disabled by the virus they are no longer fit for work. Employees who have been ill for two years and unable to work or work full time are eligible for
    A majority of people with Long Covid who are registered with state benefits agency UWV have been so disabled by the virus they are no longer fit for work. Employees who have been ill for two years and unable to work or work full time are eligible for
    www.dutchnews.nl
  • G
    G
    The smell of money !!
  • l
    luca
    When can we expect next news release
  • O
    Oren
    Great news release Saturday on the Dale's report.. 😀
  • C
    Cliff
  • e
    eric
    Slowly but GREEN
  • e
    eric
    FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization

    TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

    Scroll to continue with contentAd

    L'électrique, maintenant pour tous.
    Following the Company receiving positive comments from the FDA in regards to the Company's request to determine and agree on the Study's potential new primary efficacy endpoints and the Company’s submission of a Data Access Plan (“DAP”) to the FDA, the FDA has accepted the DAP to allow for the unblinding of the pre-dose selection data. The Company will now proceed to unblind the pre-dose selection data to potentially support the amended Study protocol with the new primary efficacy endpoints. The proposed new primary efficacy endpoints may include the rate of sustained clinical resolution of symptoms of COVID-19, which addresses the shift in COVID-19 clinical outcome observed over the course of the pandemic, and, therefore, to have more meaningful study endpoints for the FDA to consider for potential Emergency Use Authorization.

    The Company believes that with the Omicron variant, including the BA.2 variant, being the dominant strain over the Delta variant, there is an urgent need to treat symptom resolutions in addition to preventing hospitalizations.
  • R
    RS
    Bringing some friends on board in Canada. Where is best to set up account like E*trade or something to buy? Thanks!!